Cambridge GaN Devices Secures Investment from British Patient Capital and Parkwalk

Cambridge GaN Devices (CGD), a leading designer, developer, and manufacturer of Gallium Nitride (GaN) transistors and Integrated Circuits (ICs), has announced it has secured an investment from British Patient Capital and Parkwalk, the most significant growth EIS fund manager in the UK.

The investment will enable CGD to accelerate its growth plans. It will focus on the development and commercialization of its high-efficiency GaN transistors and ICs for various applications, including power electronics, RF, and sensor technologies.

British Patient Capital is a wholly owned commercial subsidiary of the UK government’s economic development bank, British Business Bank plc. Its mission is to enable long-term investment in innovative firms led by ambitious entrepreneurs who want to build large-scale businesses.

Parkwalk invests in businesses creating solutions to real-world challenges, with IP-protected innovations, across a range of sectors including life sciences, AI, quantum computing, advanced materials, genomics, cleantech, future of mobility, medtech, and big data.

CGD’s technology is protected by a strong IP portfolio, which constantly grows based on the company’s leading innovation skills and ambitions. The company’s GaN transistors and ICs are designed to deliver the most efficient and reliable power electronics, enabling a radical step change in energy efficiency and compactness, making them suitable for high-volume production.